The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure

被引:28
作者
Amin, N [1 ]
机构
[1] Genzyme Corp, Cambridge, MA 02139 USA
关键词
calcium; chronic renal failure; hyperphosphataemia; phosphate binder; phosphorus; sevelamer hydrochloride;
D O I
10.1093/ndt/17.2.340
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Phosphorus control is a primary goal in the care of patients with end-stage renal disease (ESRD). Sevelamer hydrochloride, a novel calcium-free, aluminum-free phosphate binder, allows physicians to control serum phosphorus in patients with ESRD without increasing serum calcium levels or contributing an excess calcium load. Clinical studies have shown that sevelamer provides sustained reduction in markers of soft-tissue and cardiac calcification, specifically serum phosphorus, calcium x phosphorus product, parathyroid hormone and also improves blood lipid profiles. Thus, sevelamer hydrochloride offers the promise of impacting cardiac calcification and thereby reducing patient morbidity and mortality. Long-term Studies are underway to evaluate these potential benefits. This paper reviews sevelamer studies to date and addresses ongoing strategies for improving clinical management of phosphorus in ESRD.
引用
收藏
页码:340 / 345
页数:6
相关论文
共 18 条
[1]   EXCESS PTH IN CRF INDUCES PULMONARY CALCIFICATION, PULMONARY-HYPERTENSION AND RIGHT-VENTRICULAR HYPERTROPHY [J].
AKMAL, M ;
BARNDT, RR ;
ANSARI, AN ;
MOHLER, JG ;
MASSRY, SG .
KIDNEY INTERNATIONAL, 1995, 47 (01) :158-163
[2]   A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients [J].
Bleyer, AJ ;
Burke, SK ;
Dillon, M ;
Garrett, B ;
Kant, KS ;
Lynch, D ;
Rahman, SN ;
Schoenfeld, P ;
Teitelbaum, I ;
Zeig, S ;
Slatopolsky, E .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (04) :694-701
[3]   Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management [J].
Block, GA ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (06) :1226-1237
[4]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[5]   Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients [J].
Braun, J ;
Oldendorf, M ;
Moshage, W ;
Heidler, R ;
Zeitler, E ;
Luft, FC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (03) :394-401
[6]   Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients [J].
Chertow, GM ;
Burke, SK ;
Dillon, MA ;
Slatopolsky, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (12) :2907-2914
[7]  
Collins AJ, 2000, CLIN NEPHROL, V54, P334
[8]  
Drueke TB, 1996, NEPHROL DIAL TRANSPL, V11, P37
[9]   Clinical epidemiology of cardiovascular disease in chronic renal disease [J].
Foley, RN ;
Parfrey, PS ;
Sarnak, MJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S112-S119
[10]   Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis [J].
Goodman, WG ;
Goldin, J ;
Kuizon, BD ;
Yoon, C ;
Gales, B ;
Sider, D ;
Wang, Y ;
Chung, J ;
Emerick, A ;
Greaser, L ;
Elashoff, RM ;
Salusky, IB .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1478-1483